NASDAQ:GBT - Nasdaq - US37890U1088 - Common Stock - Currency: USD
Taking everything into account, GBT scores 2 out of 10 in our fundamental rating. GBT was compared to 555 industry peers in the Biotechnology industry. Both the profitability and financial health of GBT have multiple concerns. GBT is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -37.05% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | -127.41% | ||
PM (TTM) | -137.3% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 4.92 | ||
Debt/FCF | N/A | ||
Altman-Z | 1.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 6.88 | ||
Quick Ratio | 6.17 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | -15.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
68.49
+0.01 (+0.01%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 19.68 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 39.05 | ||
P/tB | N/A | ||
EV/EBITDA | -15.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -37.05% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | -127.41% | ||
PM (TTM) | -137.3% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 4.92 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 6.88 | ||
Quick Ratio | 6.17 | ||
Altman-Z | 1.24 |